Clinical Trial

Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis

Name: Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis — clinical trial record (NCT07683806)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This study will assess the safety and efficacy of Roflumilast foam 0.3% (ZORYVE®) versus vehicle applied once a day for 8 weeks by trial participants with seborrheic dermatitis.

Trial Details

NCT Number	NCT07683806
Lead Sponsor	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Collaborators: Arcutis Biotherapeutics, Inc.
Conditions	Seborrheic Dermatitis
Enrollment	309 participants
Start Date	2026-08-24
Primary Completion	2027-06-30 (estimated)
Study Completion	2027-08-03 (estimated)
Updated on ClinicalTrials.gov	2026-07-06